OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
CAMBRIDGE, Mass., May 30, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announced that it is scheduled to present at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 10:40 a.m. PT (1:40 p.m. ET). Edward Kaye, Sarepta’s chief executive officer, will be the presenter at the fireside chat.
The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
